Loading data for CLDI — first visit, this takes a few seconds.
Calidi Biotherapeutics In... (CLDI)
NYSE American: CLDI
· Real-Time Price · USD
1.42
+0.15 (11.81%)
At close: Aug 18, 2026, 3:58 PM
Calidi Biotherapeutics Inc. (CLDI) Stock Price, Analysis & Data
11.81% (1D)
| Bid | 1.41 |
| Market Cap | 3.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.45M |
| Beta | n/a |
| EPS (ttm) | -37.04 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.53 |
| P/B (ttm) | 0.62 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.46 |
| Volume | 109,964 |
| Avg. Volume (20D) | 325,409 |
| Open | 1.25 |
| Previous Close | 1.27 |
| Day's Range | 1.29 - 1.46 |
| 52-Week Range | 1.25 - 30.40 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CLDI
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-40...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 1, 2021
Employees 29
Stock Exchange NYSE American
Ticker Symbol CLDI
Website https://www.calidibio.com
Financial Performance
In 2025, Calidi Biotherapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -19.91M, a decrease of -10.1%.
Financial StatementsEarnings Surprise
Calidi Biotherapeutics has released their quarterly earnings on Nov 13, 2025: